Jan 25 (Reuters) - The world’s largest syringe maker does not have the capacity to substantially increase U.S. supplies of specialty syringes needed to squeeze more doses from Pfizer Inc COVID-19 vaccine vials in the coming weeks, an executive said in an interview.
The vaccine made by Pfizer and its German partner BioNTech, one of two authorized for U.S. emergency use, is shipped in vials initially indicated to hold five doses. Six doses can be drawn with special syringes, call low dead space, which minimize the amount of vaccine left in the syringe after use.
If healthcare providers can reliably extract the sixth dose it would allow supplies to be stretched 20% further and could be a financial boost for Pfizer, which is paid per dose.
The U.S. government has begun giving healthcare providers new syringe kits to extract six shots from each vial. It said that three of the low dead space syringes in each six-needle kit would allow extraction, according to an email reviewed by Reuters. A CDC spokeswoman said the new kits would contain a “majority” of low dead space syringes.
Syringe maker Becton Dickinson has contracted with the U.S. government to provide 286 million syringes for use with COVID-19 vaccines, including around 40 million low dead space syringes, and is fully prepared to deliver on that agreement, said Troy Kirkpatrick, the company’s senior director of public relations.
Low dead space syringes are a niche product and Becton Dickinson had not discussed plans with the U.S. government to substantially boost their output when they began preparing for the vaccine rollout last year, he said.
“We are ready to support the U.S. government but we are trying to make sure everyone understands that those devices are not something we have infinite capacity to produce and bringing up new lines does take time,” Kirkpatrick said.
The Franklin Lakes, New Jersey-based company is the largest syringe and needle maker in the world, according to 360iResearch, and Kirkpatrick said it has boosted overall production capacity by about 1 billion syringes for 2021, with most of the capacity allocated.
A new production line for syringes will be functional by July but was not designed to produce additional low dead space syringes, he said.
The federal government has contracts with other manufacturers, and it was not immediately clear whether they could supply more of the specialty syringes.
The U.S. Centers for Disease Control and Prevention (CDC), a federal organizer of the vaccination drive, told providers in an email reviewed by Reuters it has started giving healthcare providers packages including both types of needles.
The email said early testing showed that three low dead space syringes used in combination with three standard syringes may yield the sixth dose.
“Every effort is being made to reconfigure the ancillary kits with syringes that enable the six dose draw without impacting the availability or slowing the delivery of supplies to jurisdictions,” the email said.
President Joe Biden has described the vaccine rollout so far as a “dismal failure” and said he will use wartime powers to secure more supplies for the campaign, including low dead space syringes, but experts say that such efforts will still run up against production constraints.
Healthcare distributor McKesson Corp is responsible for assembling the accompanying kits of vaccination supplies, including syringes, that are paired with each tray of Pfizer vaccines. The supplies themselves are procured by the U.S. government.
Moderna Inc, which makes the other vaccine authorized for use in the United States, says it puts 10 doses in each of its vials, but New York State public health officials have said providers can extract 11 doses. (Reporting by Carl O’Donnell; Editing by Caroline Humer, Peter Henderson and Daniel Wallis)
Our Standards: The Thomson Reuters Trust Principles.